real-time news and commentary for investors
Tuesday, Aug 13
More on Supernus Pharmaceuticals earnings
- Supernus Pharmaceuticals (SUPN) Q2 EPS loss comes in greater than anticipated.
- EPS -46% from the same quarter last year.
- Net product revenue of $200K, which is comprised of 529 Oxtellar XRTM prescriptions filled at the pharmacy level, with the net price of Oxtellar XR reflecting deductions for one-time discounts paid to wholesalers, as well as customary payer rebates, allowances, and the cost of a co-payment rebate program.
- Gross margin on net product revenue was 97%.